AD HOC NEWS Market update
News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 1โ36
- Matches
- 118
- Sources here
- 15
- Companies here
- 1
Active search
118 matching headlines
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Thermo Fisher Scientific Proteomics Technologies Enable Discovery of More Than 2,500 New Biological Associations in PRECISE-SG100K Study
Initial results presented at HUPO 2026 World Congress demonstrate how the company's complementary mass spectrometry and Olink biomarker panels can expand biological associations at population scale to advance disease and therapeutic development research Key Takeaways: Thermo Fisher's complementary proteomic technologies uncovered more than 2,500 โฆ
Thermo Fisher Scientific (TMO) Stock Seems Reasonable Following Its 47% Run
Thermo Fisher Scientific has been a strong performer over the past year, and that kind of run naturally raises a pointed question for anyone looking at the stock today. Is the current share price aligned with the cash flows the business is expected to โฆ
Thermo Fisher (TMO) Is Turning Innovation Into Recurring Revenue. Can Margins Follow?
On September 23, Thermo Fisher Scientific Inc. (NYSE:TMO) announced the launch of the Gibco CHO-K1 Catalog Panel, a cGMP-ready portfolio of basal and feed media designed to accelerate cell growth and protein production for CHO-K1 host lines used in biologics and biosimilars development. Offered โฆ
Will Thermo Fisherโs New cGMP CHO-K1 Panel and MRD Moves Change Thermo Fisher Scientific's (TMO) Narrative
Earlier this month, Thermo Fisher Scientific announced several product and collaboration updates, including the cGMP-ready Gibco CHO-K1 Catalog Panel for bioprocessing, a reseller agreement to distribute Evosep's Eno separation platform in proteomics workflows, and expanded involvement in molecular residual disease programs with Biodesix and โฆ
Gilead vs. Thermo Fisher: Which Life Sciences Stock has the Stronger Growth Outlook?
Gilead Sciences, Inc. (NASDAQ:GILD) and Thermo Fisher Scientific Inc. (NYSE:TMO) are benefiting from two very different sources of growth. Gilead's momentum is being driven primarily by its HIV portfolio, where established medicines and newer products are expanding rapidly. Thermo Fisher, meanwhile, is beginning to โฆ
Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 21, 2026
WALTHAM, Mass., September 28, 2026--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the third quarter 2026 before the market opens on Wednesday, October 21, 2026, and will hold a conference โฆ
Thermo Fisher Scientific and Evosep Enter Reseller Agreement for Evosep Eno
Evosep Thermo Fisher Scientific to offer the Evosep Eno separation platform to customers, expanding access to standardized, high-throughput proteomics workflows SINGAPORE, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Evosepโข, a global leader in standardized proteomics solutions, today announced a reseller agreement with Thermo Fisher Scientific, โฆ
Pfizer vs. Thermo Fisher: Which Healthcare Turnaround has More Upside?
Pfizer Inc. (NYSE:PFE) and Thermo Fisher Scientific Inc. (NYSE:TMO) are both trying to put difficult post-pandemic periods behind them, but their recoveries look very different. Thermo Fisher is benefiting from improving activity across life-sciences markets after a prolonged slowdown in pharmaceutical and biotech spending. โฆ
Here's How Much a $1000 Investment in Thermo Fisher Scientific Made 10 Years Ago Would Be Worth Today
For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and industries. Another factor that can influence investors is FOMO, or the fear of โฆ
Thermo Fisher Scientific (TMO) Launches Gibco CHO K1 Panel On A Fair Value Question
Thermo Fisher Scientific (TMO) has introduced the Gibco CHO-K1 Catalog Panel, a cGMP-ready media portfolio aimed at improving cell growth, protein yield, and workflow flexibility for biologics and biosimilars developers. Thermo Fisher Scientific sits at US$665.30 per share after a 30-day share price return โฆ
Thermo Fisher Scientific (TMO) Rolls Out New Media Panel For Biologics Development
Thermo Fisher Scientific (NYSE:TMO) has introduced the Gibco CHO-K1 Catalog Panel, a new off the shelf media offering for biologics developers. The panel includes cGMP ready, chemically defined, animal origin free basal and feed media aimed at broad process development and manufacturing use. The โฆ
Thermo Fisher Scientific Launches Gibcoโข CHO-K1 Catalog Panel Media and Feed to Accelerate Biologics Development
New cGMP-ready media and feed panel helps developers rapidly identify high-performing combinations, with study results demonstrating up to 73% higher titer versus benchmark catalog media and feeds and up to 202% higher peak viable cell density compared with benchmark products tested Key facts Product: โฆ
Capitalize on High Content Screening Disruption: Decode How Thermo Fisher Scientific, Danaher, Revvity, and Yokogawa Are Reshaping Global R&D ROI and Revenue
Company Logo High-content screening is advancing drug discovery and personalized medicine, driven by 3D models, advanced imaging and automated analytics, with opportunities in cancer research and organoids. Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "High Content Screening (HCS) - Global Strategic Business Report" has โฆ
Capitalize on the High Throughput Screening Shift: Track Thermo Fisher, Agilent, Danaher, Revvity and Tecan as AI-Driven Drug Discovery Reshapes R&D ROI
Company Logo AI, automation, robotics, microfluidics and nanotechnology are advancing HTS, while personalized medicine, biologics, research funding and pharma-academia partnerships drive demand. Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "High Throughput Screening (HTS) - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. โฆ
Thermo Fisher Scientific (TMO) is Positioned for Resurgence
Fenimore Asset Management, an investment management company, released its Q2 2026 investor letter. You can download the letter here. U.S. equity markets saw broad gains in Q2, driven by strong corporate earnings, economic resilience, and enthusiasm for artificial intelligence (AI). Major indices reached all-time โฆ
Three Analysts, Three Verdicts on Thermo Fisher: Hereโs Who the Numbers Favor
Three Analysts, Three Verdicts on Thermo Fisher: Here's Who the Numbers Favor ยฉTIKR Key Stats for Thermo Fisher Stock Current Price: $641.39 Target Price (Mid): ~$839 Street Target: ~$645 Potential Total Return: ~31% Annualized IRR: ~7% / year What Happened? Thermo Fisher Scientific (TMO) โฆ
Why Is Thermo Fisher Scientific (TMO) Building A Massive Early Disease Data Platform?
Thermo Fisher Scientific (NYSE:TMO) and Mayo Clinic announced the formation of Precure, LLC for early disease detection using multi omic data. Precure plans to integrate proteomic, genomic, and longitudinal clinical records into a single biomedical dataset to identify early disease signals. The collaboration positions โฆ
Thermo Fisher Sees Stronger Demand, Calls 2026 an โOutstanding Yearโ
Key Points Interested in Thermo Fisher Scientific Inc.? Here are five stocks we like better. Thermo Fisher raised its outlook after returning to 5% organic growth in the second quarter, with adjusted EPS up 13%. CEO Marc Casper expects about 4% organic growth in โฆ